Mohammad OZEIR

Toxicologie, Pharmacologie et Signalisation céllulaire - UMR-S 1124
Université Paris Descartes
45 rue des Saints Pères
75270 Paris Cedex 06

Fax : +33 (0) 1 42 86 38 68

Mohammad OZEIR

Post-doctoral fellow
Pharmacology and structural biology

+33 1 42 86 40 35, room R280

Mohammad Ozeir, post-doctoral fellow in the team “PharmacoToxicology and Structural Biology” headed by Pierre Nioche is mainly interested in the mechanism of the recognition and processing of chemical molecules by Cytochromes P450 (CYP) in order to prevent the spread of potentially carcinogenic ligands. He is primarily involved in solving CYP structures, from native or natural variants in complex with different mutagenic or toxic compounds.

After graduating from the Lebanese University with a bachelor in biology, and University of Joseph Fourier (UJF) with a Masters in Cellular and Integrative Biology, Mohammad Ozeir obtained a Ph.D in biochemistry from UJF Grenoble (2012) under the supervision of Prof. Marc Fontecave and Dr. Fabien Pierrel. His thesis focused on the study of the biosynthetic pathway of coenzyme Q in Saccharomyces cerevisiae. After his Ph.D, he joined the INSERM Unit UMR-S 1124 on an ATER (Temporary Attached for Education and Research) position in 2012, which was renewed until the end of August 2014. Meanwhile, Mohammad was responsible for teaching Biochemistry courses for first year medical students (PACES) and preparing entrance exams. He was also involved in a research project within the team of Pierre Nioche during which he solved by X-ray crystallography cytochrome P450 (CYP) structures in complex with different toxic and carcinogenic ligands. This work is part of a wider project in structural biology aiming to understand xenobiotic recognition mechanism.

In the frame of this project, Mohammad was funded for a three years post-doctoral fellowship by the “ARC Foundation for Cancer Research” starting on September 2014.

The results obtained during this project will allow:

  • To better understand the molecular mechanisms of cytochrome P450 in the recognition of ligands.
  • Modeling of new specific anti-cancer inhibitors of CYP1 family.
  • To better understand the metabolic changes associated with natural variants of CYP.
  • To establish a predictive model able to estimate the potential ab initio in terms of toxicity and mutagenicity of all new molecules which humans may be exposed to.

Recent Publications